The only second-generation JAK inhibitor selective for relief of itch and inflammation
Relief never felt so simple
Relief never felt so simple
Selective & Effective Relief
Numelvi® (atinvicitinib tablets) is a second-generation Janus kinase (JAK) inhibitor.
Numelvi® provides an effective first-line treatment in dogs 6 months of age and older and is indicated for
- pruritus associated with allergic dermatitis and atopic dermatitis
- clinical manifestations of atopic dermatitis
The only JAK inhibitor at least 10X more selective for JAK1*¹, providing a favourable safety profile1 and owner peace of mind.
The only JAK inhibitor licensed in dogs as young as 6 months old.¹
Starts relieving itch within 2–4 hours**, providing dogs and owners relief quickly.
Once-daily dosing from day 1¹, keeping it simple, reducing up-front costs and eliminating rebound itch.
Why selectivity matters
Numelvi is the only second-generation JAK inhibitor selective for itch and inflammation in dogs.
JAK1 is the primary driver of itch and inflammation2
High selectivity for JAK1 helps minimise interference with other JAK enzymes crucial for immune system function and haematopoiesis1
First-generation JAK inhibitors target JAK enzymes with little to no selectivity3
Numelvi is at least 10x more selective for JAK1* ¹, providing a favourable safety profile¹ and owner peace of mind
Dr Stephen Shaw on why JAK selectivity matters
How selectivity supports safety
Because Numelvi is more than 10x selective for JAK1*, it gives owners peace of mind by providing:
- A favourable safety profile¹
- The only JAK inhibitor licensed for dogs as young as 6 months1
- No known interactions with routine treatment¹
- No adverse clinical effects related to treatment when used concomitantly with vaccination, including rabies vaccination¹
- No requirements for periodic blood and urine monitoring¹
- Reduced inflammation-associated white blood cell counts (within reference range)1
How selectivity supports safety
Because Numelvi is at least 10x as selective for JAK1*, it gives owners peace of mind by providing:
- A favourable safety profile¹
- The only JAK inhibitor licensed for dogs as young as 6 months1
- No known interactions with routine treatments¹
- No adverse clinical effects related to treatment when used concomitantly with vaccination, including rabies vaccination¹
- No requirements for periodic blood and urine testing¹
- Reduced inflammation-associated white blood cell counts (within reference range)1
The future of itch relief
offers reassuring safety for patients.
Numelvi provides quick and effective relief
Itch relief starts within 2-4 hours**
Significant reduction in itch from the first dose4
Clinically relevant reduction in itch in >81% of dogs within 1 week4
Reduction of allergy-mediated inflammation
Available in 4 Convenient Strengths
Simple dosing: dogs weighing 3.0–39.5 kg require half or one tablet daily
Dogs outside the listed weight bands, for example dogs above 79 kg bodyweight, can be dosed with a combination of full and/or half tablets of the appropriate tablet strengths to achieve a target dose of 0.8–1.2 mg atinvicitinib/kg bodyweight. Available tablet strengths do not allow for accurate dosing of dogs weighing less than 2 kg bodyweight.
Compare Numelvi® to first-generation JAK inhibitors
*Over the other JAK enzymes in in vitro assays.
Have a question about Numelvi®?
Simplicity and Convenience
Simple for Veterinarians
- Proven safety profile for dogs and puppies as young as 6 months of age
- Available in pack sizes of 30 and 90 tablets
- Available in four pack strengths (4.8 mg, 7.2 mg, 21.6 mg & 31.6 mg)
- Does not require any special storage conditions
- Shelf life as packaged for sale is 36 months
Simple for Pet Owners
- Once-daily dosing from the start
- Consistent itch relief with consistent dosing
- Reassuring safety profile
Experts and Case Studies
Eleanor Hughes – Advanced Practitioner in Small Animal Dermatology
“It is more specific, less side effects because it’s selective. Once daily dosing, it’s very quick onset and people don’t have to remember to change the dose.”
Simon Want – Advanced Practitioner in Veterinary Dermatology
“I am very excited, there is a new entry for a new JAK inhibitor for treating atopic dermatitis, giving us more options to treat more of our pets.”
Debbie Gow – RCVS-recognised and EBVS® Specialist in Veterinary Dermatology
“The more selective these products are, then in theory the less side effects we would have. So, I think that’s a really nice new product to have available.”
Case Studies
These dog’s names have been changed for privacy reasons.
Max
Background:
This is Max, a beautiful 3-year-old 42kg Golden Retriever living in Romania who has had ongoing skin issues since the age of 1. Unfortunately for Max, the previous treatments he had trialled (including dexamethasone, lokivetmab and oclacitinib) only provided minimal success. In terms of ectoparasite control, Max is up to date with Bravecto Injectable®.
Prior to trying Numelvi, Max’s clinical signs included being intensely itchy, recurrent bouts of otitis externa and severe paw licking that lead to hair loss as well as lesions on his feet.
Initial treatment:
Max was started on Numelvi for 2 months alongside treatment for his ears and a combination of wipes and shampoo. This has made a considerable improvement to all his clinical signs including hair regrowth!
Ongoing plan:
To continue on Numelvi and concurrent therapies long-term.
Before
After
Joe
Background:
Meet Joe, a gorgeous 7-year-old crossbreed living in Romania weighing 22kg. Unfortunately, Joe has suffered from atopic dermatitis since he was 4.
Joe initially tried oclacitinib but had poor results so his vet decided to swap him onto lokivetmab. This did help, however, the injections were only lasting for 2 weeks.
Joe’s clinical signs included itchiness, hair loss, discolouration of his lip folds and hyperpigmentation. Joe is regularly treated for ectoparasites.
Initial treatment:
Numelvi was started for 2 months alongside his parasite treatment and wipes which resulted in significant itch relief, resolution of the red skin and hair regrowth.
Ongoing plan:
To continue with this initial treatment plan long-term.
Before
After
Dexter
Background:
Here we have Dexter, a little 5-year-old Yorkshire Terrier who has suffered from chronic itch from the age of 2. Dexter had previously tried methylprednisolone, oclacitinib and dexamethasone with little success and the clinical signs he presented with were chronic itch, hyperpigmentation and redness in the paws, front legs and perianal area.
Initial treatment:
Dexter was started on Numelvi for one month along with wipes, with his symptoms almost completely resolving (there was still some remaining redness in one paw).
Ongoing plan:
To continue with this initial treatment plan long-term.
Before
After
Want to learn more about Numelvi?
* Over the other JAK enzymes in in vitro assays.
** Based on a canine interleukin-31 induced pruritus model
References
- Numelvi® Summary of product characteristics
- Huang IH, Chung WH, Wu PC, et al. Front Immunol. 2022;13:1068260. doi: 10.3389/fimmu.2022.1068260
- Gonzalez AJ, Bowman JW, Fici GJ, et al. J Vet Pharmacol Ther. 2014;37(4):317-324
- MSD Animal Health MSD Internal Study Summary REF 11194. MSD Animal Health
- Cosgrove SB, Wren JA, Cleaver DM, et al. Vet Dermatol. 2013;24(5):479-e114
Numelvi® tablets for dogs contains atinvicitinib. POM-V. Further information is available from the SPC, datasheet or package leaflet. Advice should be sought from the medicine prescriber. Prescription decisions are for the person issuing the prescription alone. Use Medicines Responsibly.
Want to make itch relief simple in your practice? Fill in the form below today.
Please fill out the form below to request a call from an MSD Animal Health representative.
“*” indicates required fields
